English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 904011      Online Users : 783
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15719


    Title: Use of leukotriene-receptor antagonists and risk of neuropsychiatric adverse events: A nationwide population-based cohort study
    Authors: Kao, HF;Tsai, HJ;Chang, YC;Tsai, YF;Yao, TC
    Contributors: Institute of Population Health Sciences
    Abstract: Background: Leukotriene-receptor antagonists (LTRA) are a class of remedies commonlyused for treating patients with asthma and/or allergic rhinitis. However, the evidence aboutthe association between LTRA use and neuropsychiatric adverse events from observationalstudies has been inconclusive. Most results are based on pediatric populations, little is knownin relation to potential neuropsychiatric adverse events among adults, especially Asianpopulations. Method: We used medical claims data derived from the entire National Health InsuranceResearch Database in Taiwan to identify study patients during 2008 and 2018. Exposure wasdefined as patients having at least 1 dispensed prescription for LTRA after asthma diagnosisduring study period. Inverse probability of treatment weighting using propensity score wasapplied to control for the systematic differences at baseline between LTRA users and non-users. Main outcomes are primary diagnoses of neuropsychiatric adverse events (psychoticdisorder, mood disorder, anxiety disorder, sleep-related disorder, cognitive disorder,movement disorder, and personality disorder) during the subsequent 12 months afterinitiation. Cox proportional hazards models with covariate adjustment were performed todetermine the associations between LTRA exposure and neuropsychiatric adverse events. Results: A total of 1,010,556 patients with asthma (222,075 LTRA users and 788,481 non-users) was identified in the study cohort. The results suggest positive significant associationsof LTRA exposure with psychotic disorder and movement disorder among study patients(adjusted hazard ratio (AHR) = 1.59; 95% confidence interval (CI): 1.07-2.36 for psychoticdisorder and AHR = 1.34; 95% CI: 1.01-1.77 for movement disorder). Conclusion: This study suggests that LTRA use is associated with increased risk ofneuropsychiatric adverse events, specifically psychotic disorder and movement disorder,during the subsequent 12 months after LTRA initiation. Our findings suggest that cliniciansadministering LTRA to patients with asthma should monitor potential neuropsychiatricadverse events during LTRA treatment.
    Date: 2023-12
    Relation: Allergy. 2023 Dec;78(Suppl. 112):471.
    Link to: http://dx.doi.org/10.1111/all.15925
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0105-4538&DestApp=IC2JCR
    Appears in Collections:[蔡慧如] 會議論文/會議摘要

    Files in This Item:

    File Description SizeFormat
    ISI001144363000365.pdf369KbAdobe PDF48View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback